

Supplementary Data

DOI: 10.24875/AIDSRev.M25000081

Supplementary Table 1. Cohort studies, randomized clinical trials and control case studies assessing the association between abacavir and cardiovascular events

Study	Study Design	Age, years (range)	Event (n)	Pts, N	ABC CV Effect	Time on ABC, months	Risk of MI (95% CI)
D:A:D ^[1]	Cohort	40 (35-47)	MI, validated (387)	22,625	Yes	≥ 6	2.04 (1.66-2.51)
D:A:D 2015 ^[2]	Cohort	39 (33-46)	MI (493)	32,663	Yes	Current	1.47 (1.26-1.71)
SMART ^[3]	RCT	45 (39-51)	MI, validated (19)	2752	Yes	Current	4.3 (1.4-13.0)
STEAL ^[4]	RCT	45.7 ± 8.8	MI (4)	357	Yes	96	2.79 (1.76-4.43)
QPHID ^[5]	CC	47 (22-67)	MI (125)	7053	Yes	Any	1.79 (1.16-2.76)
Danish ^[6]	Cohort	39 (33-47)	MI (67)	2952	Yes	> 6	2.00 (1.07-3.76)
VA (Choi) ^[7]	Cohort	46	CVD event (501)	10,931	Yes	Recent	1.64 (0.88-3.08)
Swiss ^[8]	Cohort	NR	CVD event (365)	11,856	Yes	Recent	4.06 (2.24-7.34)
MAGNIFICENT ^[9]	CC	50 (22-85.5)	CVD event (571)	1875	Yes	Current	1.56 (1.17-2.07)
NA-ACCORD ^[10]	Cohort	NR	MI, validated (301)	16,733	Yes	Recent	1.33
FHDH ^[11]	CC	47 (41-54)	MI (289)	74,958	No	< 12/recent	1.27 (0.64-2.49)
ALLRT/ACTG ^[12]	Cohort	37 (26-51)	MI (36)	5056	No	72	0.6 (0.3-1.4)
VA ^[13]	Cohort	46	MI (278)	19,424	No	Per 12	1.18 (0.92-1.50)
FDA ^[14]	MA of RCTs	36-42	MI (46)	9868	No	19	1.02 (0.56-1.84)

ABC: abacavir; CC: control case; CV: cardiovascular; CVD: cardiovascular disease; MA: meta-analysis; MI: myocardial infarction; NR: not reported; RCT: randomized clinical trials.

1. Friis-Møller N, Thiébaud R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil*. 2010 Oct;17(5):491-501.
2. Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. *Eur J Prev Cardiol*. 2016 Jan;23(2):214-23.
3. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. *AIDS*. 2008 Sep 12;22(14):F17-24.
4. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial. *Clin Infect Dis* 2009;49(10):1591–601.
5. Durand M, Sheehy O, Baril JG, Leloir J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: A cohort and nested case-control study using Québec's Public Health Insurance database. *J Acquir Immune Defic Syndr*. 2011;57(3):245-253.
6. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. *HIV Med* 2010;11(2):130–6.
7. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li YM, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. *AIDS* 2011;25(10):1289–98.
8. Young J, Xiao Y, Moodie EEM, Abrahamowicz M, Klein MB, Bernasconi E, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2015;69(4):413–21.
9. Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. *Clin Infect Dis* 2013;57(1):112–21.
10. Palella FJ Jr, Althoff K, Moore R, Zhang J, Kitahata M, Gange SJ, et al. Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD. *CROI 2015, Seattle, USA*; 2015. February 23–26.
11. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. *Arch Intern Med*. 2010 Jul 26;170(14):1228-38.
12. Ribaud HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-term results from ACTG A5001/ALLRT. *Clin Infect Dis* 2011; 52(7):929–40.
13. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. *Clin Infect Dis* 2011; 53(1):84–91.
14. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr*. 2012 Dec 1;61(4):441-7.